

Supplemental Figure S1. Pharmacokinetic (PK) modeling to describe the clinical data of anetumab ravtansine as a model DM4-ADC. (A) A two-compartment model is used to characterize the disposition of anetumab ravtansine. ADC elimination clearance was set as the formation clearance of DM4. The systemic PK of DM4 and its major catabolite, S-Methyl-DM4 (SMeDM4), is represented with a one-compartment model. A complete description of the model structure is provided in the methods section. (B) Simultaneous fitting of the PK model to clinical data of anetumab ravtansine. The model fitted the plasma concentration vs. time profiles of ADC and SMeDM4 reasonably well, with an over-prediction of the DM4 terminal concentrations.